FORMA THERAPEUTICS HOLDINGS, INC. Research and Development Expense
FORMA THERAPEUTICS HOLDINGS, INC. reported Research and Development Expense of $39.06 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-05
- FORMA THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2022-06-30 was $39.06M, a 23.66% increase year-over-year.
- FORMA THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2022-03-31 was $31.27M, a 18.71% increase year-over-year.
- FORMA THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2021-12-31 was $37.05M, a 48.99% increase year-over-year.
- FORMA THERAPEUTICS HOLDINGS, INC. research and development expense for the quarter ending 2021-09-30 was $30.68M, a 23.83% increase year-over-year.
- FORMA THERAPEUTICS HOLDINGS, INC. research and development expense for fiscal 2021 was $125.66M, a 34.59% increase from fiscal 2020.
- FORMA THERAPEUTICS HOLDINGS, INC. research and development expense for fiscal 2020 was $93.37M, a 16.12% decline from fiscal 2019.
- FORMA THERAPEUTICS HOLDINGS, INC. research and development expense for fiscal 2019 was $111.31M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $39.06M 10-Q · filed 2022-08-05 | $70.33M 10-Q · filed 2022-08-05 | $107.38M derived: sum of 3 quarters · filed 2022-08-05 | $138.06M derived: sum of 4 quarters · filed 2022-08-05 |
| 2022-03-31 | $31.27M 10-Q · filed 2022-05-06 | $68.32M derived: sum of 2 quarters · filed 2022-05-06 | $99.00M derived: sum of 3 quarters · filed 2022-05-06 | $130.59M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-12-31 | $37.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $67.73M derived: sum of 2 quarters · filed 2022-03-01 | $99.32M derived: sum of 3 quarters · filed 2022-08-05 | $125.66M 10-K · filed 2022-03-01 |
| 2021-09-30 | $30.68M 10-Q · filed 2021-11-12 | $62.27M derived: sum of 2 quarters · filed 2022-08-05 | $88.61M 10-Q · filed 2021-11-12 | $113.48M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-06-30 | $31.59M 10-Q · filed 2022-08-05 | $57.93M 10-Q · filed 2022-08-05 | $82.80M derived: sum of 3 quarters · filed 2022-08-05 | $107.58M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $26.34M 10-Q · filed 2022-05-06 | $51.21M derived: sum of 2 quarters · filed 2022-05-06 | $75.99M derived: sum of 3 quarters · filed 2022-05-06 | $96.50M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $24.87M 10-K · filed 2021-03-30 | $49.65M derived: sum of 2 quarters · filed 2021-11-12 | $70.16M derived: sum of 3 quarters · filed 2021-11-12 | $93.37M 10-K · filed 2022-03-01 |
| 2020-09-30 | $24.78M 10-Q · filed 2021-11-12 | $45.29M derived: sum of 2 quarters · filed 2021-11-12 | $68.50M 10-Q · filed 2021-11-12 | $95.54M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $20.51M 10-Q · filed 2021-08-13 | $43.72M 10-Q · filed 2021-08-13 | $70.76M derived: sum of 3 quarters · filed 2021-08-13 | $98.32M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $23.21M 10-Q · filed 2021-05-14 | $50.25M derived: sum of 2 quarters · filed 2021-05-14 | $77.81M derived: sum of 3 quarters · filed 2021-05-14 | $105.88M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $27.04M 10-K · filed 2021-03-30 | $54.60M derived: sum of 2 quarters · filed 2021-03-30 | $82.67M derived: sum of 3 quarters · filed 2021-03-30 | $111.31M 10-K · filed 2021-03-30 |
| 2019-09-30 | $27.56M 10-K · filed 2021-03-30 | $55.62M derived: sum of 2 quarters · filed 2021-03-30 | $84.27M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $28.07M 10-K · filed 2021-03-30 | $56.72M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $28.65M 10-K · filed 2021-03-30 |